Related Experiment Video
Updated: Nov 4, 2025

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
Published on: May 5, 2018
Cardiovascular adverse events in pregnancy: A global perspective
1Aswan Heart Centre, Aswan, Egypt.
Insights
Pregnant women with heart disease face serious cardiovascular risks during and after pregnancy. Early awareness and management strategies, including specialized clinics, can prevent many maternal deaths from these events.
Area of Science:
- Cardiology
- Obstetrics
- Maternal Health
Background:
- Cardiovascular adverse events (AE) are a major cause of maternal mortality and morbidity globally.
- These events can be directly caused by pregnancy or related to pre-existing conditions, posing risks throughout pregnancy and postpartum.
- There is a growing understanding of the long-term link between pregnancy-related cardiovascular issues and future cardiovascular disease (CVD).
Purpose of the Study:
- To discuss the global distribution of cardiovascular maternal mortality.
- To review adverse cardiovascular events during and after pregnancy, including their predictors and risk stratification.
- To explore preventative solutions, highlighting the role of cardio-obstetric clinics.
Main Methods:
- Review of global data on cardiovascular maternal mortality.
- Analysis of adverse events, their causes (direct/indirect), and risk factors.
- Discussion of preventative strategies and management models like cardio-obstetric clinics.
Main Results:
- Cardiovascular adverse events represent a significant and often preventable cause of maternal mortality worldwide.
- Risk stratification and early identification of predictors are crucial for managing these events.
- Cardio-obstetric clinics show promise as a solution for improving care and outcomes.
Conclusions:
- Increasing awareness of cardiovascular risks in pregnancy is vital for prevention.
- Implementing targeted prevention and treatment strategies can reduce maternal mortality.
- Specialized cardio-obstetric services are essential for managing pregnant women with heart disease and mitigating risks.
Abstract:
Pregnant women with heart disease are vulnerable to many adverse cardiovascular events (AE). AEs during and after pregnancy continue to be important causes of maternal mortality and morbidity worldwide, with huge variations in burden in different countries and regions. These AEs are classified as having direct or indirect causes, depending on whether they are directly caused by pregnancy or due to some pre-existing disease and/or non-obstetric cause, respectively. The risks continue throughout pregnancy and even after childbirth. Apart from immediate complications during pregnancy, there is increasing evidence of a significant link between several events and the risk of cardiovascular disease (CVD) later in life. A significant number of pregnancy-related deaths caused by cardiovascular disease are preventable. This prevention can be realized through increasing awareness of cardiovascular AE in pregnancy, coupled with the application of strategies for prevention and treatment. Knowledge of the risks associated with CVD and pregnancy is of extreme importance in that regard. We discuss the global distribution of cardiovascular maternal mortality, adverse events during and after pregnancy, their predictors and risk stratification. In addition, we enumerate possible solutions, particularly the role of cardio-obstetric clinics.
More Related Videos
Related Concept Videos
Teratogenicity
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Cardiovascular Drugs: Classification based on Therapeutic Indications
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

